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To the Editor: Incidence of pulmonary nontubercu-
lous mycobacterial disease (PNTMD) is reportedly increas-
ing globally (1,2). Although such an increase is expected 
in Japan (3,4), the epidemiologic situation is unclear. The 
most recent survey, which used the 1997 American Tho-
racic Society diagnostic criteria, reported that the incidence 
rate for PNTMD in 2007 was 5.7 cases per 100,000 person-
years (5). To update the data, we performed a nationwide 
hospital-based survey in Japan.
After a preliminary survey of 20 hospitals, we devel-
oped and disseminated questionnaires to all 884 hospitals 
in Japan that were certified by the Japanese Respiratory 
Society. The surveys asked about the number of newly 
diagnosed cases, from January through March 2014, of 
PNTMD, pulmonary Mycobacterium avium disease, M. in-
tracellulare disease, or M. avium complex (MAC; the com-
bination of the first 2 species listed); pulmonary M. kansasii 
disease; pulmonary M. abscessus disease; and tuberculosis 
(TB) for inpatients and outpatients. Hospital respondents 
returned the completed questionnaires by mail, fax, or In-
ternet. To avoid potential reporting bias and misclassifica-
tion, we counted only cases that met the 2007 American 
Thoracic Society/Infectious Diseases Society of America 
statements (6) and excluded cases diagnosed at other hos-
pitals. Because the source population can be ascertained by 
using the epidemiologic data for TB as a reportable dis-
ease, to estimate the incidence rate of PNTMD, we used 
the ratio of TB to PNTMD cases. The PNTMD incidence 
rate was calculated as the national incidence rate of TB 
multiplied by the ratio of new PNTMD to TB cases report-
ed by the responding hospitals (online Technical Appendix 
Figure 1, http://wwwnc.cdc.gov/EID/article/22/6/15-1086-
Techapp1.pdf).
To clarify the chronologic changes in incidence, we 
followed the same method for comparing TB and PNTMD 
used in a prior epidemiologic study in Japan (5). We estab-
lished methods for maximizing survey response rates and 
facilitating ease of completion by offering extensive support 
to survey recipients (online Technical Appendix Table 1).
We achieved a high response rate of 62.3% (551 hos-
pitals), and in all regions the response rate exceeded 50% 
(online Technical Appendix Table 2). The numbers of newly 
diagnosed cases were 2,327 for TB and 2,652 for PNTMD. 
Because the incidence rate for TB was reported to be 12.9 
cases per 100,000 person-years, that of PNTMD was esti-
mated to be 14.7 cases per 100,000 person-years, which is 
≈2.6 times the incidence rate reported in 2007 (Figure). By 
using the same method, we found the incidence of pulmo-
nary MAC, M. kansasii, and M. abscessus disease to be 13.1, 
0.6, and 0.5 cases per 100,000 person-years, respectively 
(online Technical Appendix Table 2). The ratio of pulmonary 
M. avium disease to MAC was higher in the northern and 
eastern parts of Japan, whereas the ratio of pulmonary M. in-
tracellulare disease to MAC was higher in the southern and 
western parts of Japan (online Technical Appendix Figure 1).
From this survey, we observed that the incidence rate 
of PNTMD may exceed that of TB and that incidence rates 
of PNTMD in Japan may be among the highest worldwide 
(Figure). This finding implies that the prevalence of PNT-
MD as a chronic infection is estimated to be much higher 
than that of TB.
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1Preliminary results from this study were presented at the 
American Thoracic Society 2015 International Conference;  
2015 May 15–20; Denver, Colorado, USA  
(http://www.atsjournals.org/doi/abs/10.1164/ 
ajrccm-conference.2015.191.1_MeetingAbstracts.A5268).
Figure. Incidence (no. cases/100,000 person-years) of pulmonary 
nontuberculous mycobacterial (NTM) disease, culture-positive 
tuberculosis (TB), and smear-positive TB in Japan during 1980–
2014. The nationwide survey revealed that the incidence rate of 
pulmonary NTM disease exceeds that of TB. The epidemiologic 
survey before 1988 was conducted annually by the same 
research group; subsequently, another group performed the 
epidemiologic survey only in 2001 and 2007. 
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We assume that the high rates of PNTMD in Japan are 
consistent with data suggesting that Asians are particularly 
susceptible to PNTMD (1,7,8). Other factors contributing 
to the increase might be the simplified diagnosis according 
to the 2007 American Thoracic Society/Infectious Diseases 
Society of America statements, increased awareness by 
medical staff, population aging, and increased frequency of 
medical checkups with computed tomography of the chest.
Another finding was the characteristic gradient cluster-
ing of the ratios of M. avium and M. intracellulare (online 
Technical Appendix Figure 2). This finding supports the 
widely accepted belief that environmental factors strongly 
affect the epidemiology of PNTMD; therefore, the role of 
factors such as soil, humidity, temperature, and saturated 
vapor pressure should be seriously considered (9).
We also found dramatic increases in incidence of pul-
monary M. abscessus disease and pulmonary MAC dis-
ease, whereas incidence of pulmonary M. kansasii disease 
was stable. Although we did not distinguish M. massiliense 
from M. abscessus, the incidence rate for pulmonary M. 
abscessus disease increased from 0.1 cases in 2001 to 0.5 
cases per 100,000 person-years in 2014. This epidemiolog-
ic tendency should be monitored (10).
This study has several limitations. First, differing 
characteristics between the responding and nonrespond-
ing hospitals could cause bias. Second, we did not collect 
data outside of hospitals. Third, incomplete reporting could 
undermine the accuracy of our estimates (online Technical 
Appendix Tables 3, 4). Therefore, the epidemiologic data 
should be verified by using other approaches (online Tech-
nical Appendix Table 1). 
The dramatic increase in incidence rates for PNTMD 
warrants its recognition as a major public health concern. 
Because the prevalence rates of this currently incurable 
lifelong chronic disease are estimated to be high, the effect 
on the community could be enormous. Further investiga-
tions are needed.
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To the Editor: Pertussis is a highly communicable, 
acute bacterial respiratory infection caused by Bordetella 
pertussis. In the United States, the incidence of pertussis 
declined dramatically after pertussis-containing vaccine 
was introduced in the 1940s (1,2). However, a resurgence 
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